Long circulating lectin conjugated paclitaxel loaded magnetic nanoparticles: A new theranostic avenue for leukemia therapy

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Singh, Abhalaxmi ^a   Dilnawaz, Fahima ^a   Sahoo, Sanjeeb Kumar ^a  

^a INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; LECTIN; MAGNETIC NANOPARTICLE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PACLITAXEL; STRESS ACTIVATED PROTEIN KINASE; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; MAGNETITE NANOPARTICLE;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER DIAGNOSIS; CANCER THERAPY; CELL STRAIN K 562; CIRCULATION TIME; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG UPTAKE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; IN VIVO STUDY; LEUKEMIA; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; RAT; THERANOSTIC; ANIMAL; BLOOD; CELL STRAIN HEK293; CHEMISTRY; DRUG EFFECT; ENDOCYTOSIS; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA CELL LINE; M PHASE CELL CYCLE CHECKPOINT; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR IMAGING; PATHOLOGY; PHYSICAL CHEMISTRY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CHEMISTRY, PHARMACEUTICAL; ENDOCYTOSIS; FUSION PROTEINS, BCR-ABL; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; JURKAT CELLS; K562 CELLS; LECTINS; LEUKEMIA; M PHASE CELL CYCLE CHECKPOINTS; MAGNETITE NANOPARTICLES; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MOLECULAR IMAGING; PACLITAXEL; PHYSICOCHEMICAL PROCESSES; RATS;

EID: 81155135145     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026803     Document Type: Article

References (66)

1. Jacquel A, Herrant M, Legros L, Belhacene N, Luciano F, et al. (2003) Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward the erythroid lineage. Faseb J 17: 2160-2162.
2. Terme M, Borg C, Guilhot F, Masurier C, Flament C, et al. (2005) BCR/ABL promotes dendritic cell-mediated natural killer cell activation. Cancer Res 65: 6409-6417.
3. Nagata Y, Todokoro K, (1999) Requirement of activation of JNK and p38 for environmental stress-induced erythroid differentiation and apoptosis and of inhibition of ERK for apoptosis. Blood 94: 853-863.
4. Jia L, Patwari Y, Kelsey SM, Newland AC, (2001) Trail-induced apoptosis in Type I leukemic cells is not enhanced by overexpression of bax. Biochem Biophys Res Commun 283: 1037-1045.
5. Knijn A, Brisdelli F, Ferretti A, Iorio E, Marcheggiani D, et al. (2005) Metabolic alterations in K562 cells exposed to taxol and tyrphostin AG957: 1H NMR and biochemical studies. Cell Biol Int 29: 890-897.
6. Jordan MA, Wilson L, (1998) Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 10: 123-130.
7. Goncalves A, Braguer D, Carles G, Andre N, Prevot C, et al. (2000) Caspase-8 activation independent of CD95/CD95-L interaction during paclitaxel-induced apoptosis in human colon cancer cells (HT29-D4). Biochem Pharmacol 60: 1579-1584.
8. Haldar S, Chintapalli J, Croce CM, (1996) Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56: 1253-1255.
9. Al-alami O, Sammons J, Martin JH, Hassan HT, (1998) Divergent effect of taxol on proliferation, apoptosis and nitric oxide production in MHH225 CD34 positive and U937 CD34 negative human leukaemia cells. Leuk Res 22: 939-945.
10. Gangemi RM, Tiso M, Marchetti C, Severi AB, Fabbi M, (1995) Taxol cytotoxicity on human leukemia cell lines is a function of their susceptibility to programmed cell death. Cancer Chemother Pharmacol 36: 385-392.
11. Seiter K, Feldman EJ, Traganos F, Li X, Halicka HD, et al. (1995) Evaluation of in vivo induction of apoptosis in patients with acute leukemia treated on a phase I study of paclitaxel. Leukemia 9: 1961-1966.
12. Gangemi RM, Santamaria B, Bargellesi A, Cosulich E, Fabbi M, (2000) Late apoptotic effects of taxanes on K562 erythroleukemia cells: apoptosis is delayed upstream of caspase-3 activation. Int J Cancer 85: 527-533.
13. Consolini R, Pui CH, Behm FG, Raimondi SC, Campana D, (1998) In vitro cytotoxicity of docetaxel in childhood acute leukemias. J Clin Oncol 16: 907-913.
14. Farokhzad OC, Khademhosseini A, Jon S, Hermmann A, Cheng J, et al. (2005) Microfluidic system for studying the interaction of nanoparticles and microparticles with cells. Anal Chem 77: 5453-5459.
15. Dilnawaz F, Singh A, Mohanty C, Sahoo SK, (2010) Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 31: 3694-3706.
16. Hua MY, Yang HW, Chuang CK, Tsai RY, Chen WJ, et al. (2010) Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prostate cancer. Biomaterials.
17. Jain TK, Morales MA, Sahoo SK, Leslie-Pelecky DL, Labhasetwar V, (2005) Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol Pharm 2: 194-205.
18. Chen B, Liang Y, Wu W, Cheng J, Xia G, et al. (2009) Synergistic effect of magnetic nanoparticles of Fe(3)O(4) with gambogic acid on apoptosis of K562 leukemia cells. Int J Nanomedicine 4: 251-259.
19. Chen BA, Lai BB, Cheng J, Xia GH, Gao F, et al. (2009) Daunorubicin-loaded magnetic nanoparticles of Fe3O4 overcome multidrug resistance and induce apoptosis of K562-n/VCR cells in vivo. Int J Nanomedicine 4: 201-208.
20. Cheng J, Wu W, Chen BA, Gao F, Xu W, et al. (2009) Effect of magnetic nanoparticles of Fe3O4 and 5-bromotetrandrine on reversal of multidrug resistance in K562/A02 leukemic cells. Int J Nanomedicine 4: 209-216.
21. Chen M, Kim YN, Li C, Cho SO, (2008) Preparation and characterisation of magnetite nanoparticles and their silica egg-yolk-like nanostructures: a prospective multifunctional nanostructure platform. J Phys Chem C 112: 6710-6716.
22. Lv G, He F, Wang X, Gao F, Zhang G, et al. (2008) Novel nanocomposite of nano fe(3)o(4) and polylactide nanofibers for application in drug uptake and induction of cell death of leukemia cancer cells. Langmuir 24: 2151-2156.
23. Gupta AK, Gupta M, (2005) Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26: 3995-4021.
24. Singh A, Dilnawaz F, Mewar S, Sharma U, Jagannathan NR, et al. (2011) Composite polymeric magnetic nanoparticles for co-delivery of hydrophobic and hydrophilic anticancer drugs and MRI imaging for cancer therapy. ACS Appl Mater Interfaces 3: 842-856.
25. Arya G, Vandana M, Acharya S, Sahoo SK, (2011) Enhanced antiproliferative activity of Herceptin (HER 2)- conjugated gemcitabine loaded chitosan nanoparticle in pancreatic cancer therapy. Nanomedicine Nanotechnology, Biology and Medicine.
26. Das M, Sahoo SK, (2011) Epithelial cell adhesion molecule targeted nutlin-3a loaded immunonanoparticles for cancer therapy. Acta Biomater 7: 355-369.
27. Misra R, Sahoo SK, (2010) Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy. Eur J Pharm Sci 39: 152-163.
28. Briley-Saebo K, Bjørnerud A, Grant D, Ahlstrom H, Berg T, et al. (2004) Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: implications for magnetic resonance imaging. Cell Tissue Res 316: 315-323.
29. Weissleder RBA, Neuwelt EA, Papisov M, (1995) Long-circulating iron oxides for MR imaging. Adv Drug Deliv Rev 16: 321-324.
30. Ito M, Akiyama Y, Asato R, Kubota M, Kasai Y, et al. (1991) Early diagnosis of leukoencephalopathy of acute lymphocytic leukemia by MRI. Pediatr Neurol 7: 436-439.
31. Steinbach LS, (2007) "MRI in the Detection of Malignant Infiltration of Bone Marrow"- ACommentary. American Journal of Roentgenology 188: 1443-1445.
32. Jaetao JE, Butler KS, Adolphi NL, Lovato DM, Bryant HC, et al. (2009) Enhanced leukemia cell detection using a novel magnetic needle and nanoparticles. Cancer Res 69: 8310-8316.
33. Mohanty C, Acharya S, Mohanty AK, Dilnawaz F, Sahoo SK, (2010) Curcumin-encapsulated MePEG/PCL diblock copolymeric micelles: a novel controlled delivery vehicle for cancer therapy. Nanomedicine (Lond) 5: 433-449.
34. Sahoo SK, Ma W, Labhasetwar V, (2004) Efficacy of a transferrin-conjugated paclitaxel loaded nanoparticles in a murine model of prostate cancer. Int J of Cancer 112: 335-340.
35. Bakker AB, van den Oudenrijn S, Bakker AQ, Feller N, van Meijer M, et al. (2004) C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res 64: 8443-8450.
36. Zhao X, Singh S, Pardoux C, Zhao J, Hsi ED, et al. (2009) Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia. Haematologica 95: 71-78.
37. Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, et al. (2001) Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 20: 147-155.
38. Pendergast AM, (2005) Stress and death: breaking up the c-Abl/14-3-3 complex in apoptosis. Nat Cell Biol 7: 213-214.
39. Donovan N, Becker EB, Konishi Y, Bonni A, (2002) JNK phosphorylation and activation of BAD couples the stress-activated signaling pathway to the cell death machinery. J Biol Chem 277: 40944-40949.
40. Selma Dagtas A, Gilbert KM, (2010) p21(Cip1) up-regulated during histone deacetylase inhibitor-induced CD4(+) T-cell anergy selectively associates with mitogen-activated protein kinases. Immunology 129: 589-599.
41. Bortner CD, Cidlowski JA, (1999) Caspase Independent/Dependent Regulation of K+, Cell Shrinkage, and Mitochondrial Membrane Potential during Lymphocyte Apoptosis. JBiolChem 274: 21953-21962.
42. Palandri F, Iacobucci I, Martinelli G, Amabile M, Poerio A, et al. (2008) Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. J Clin Oncol 26: 106-111.
43. Hochhaus A, Kantarjian H, Baccarani M, Lipton JH, Apperley JF, et al. (2007) Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109: 2303-2309.
44. Dumka D, Puri P, Carayol N, Lumby C, Balachandran H, et al. (2009) Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib. Leuk Lymphoma 50: 2017-2029.
45. Acharya S, Sahoo SK, (2011) Sustained targeting of Bcr-Abl + leukemia cells by synergistic action of dual drug loaded nanoparticles and its implication for leukemia therapy. Biomaterials 32: 5643-5662.
46. Palama IE, Leporatti S, de Luca E, Di Renzo N, Maffia M, et al. (2010) Imatinib-loaded polyelectrolyte microcapsules for sustained targeting of BCR-ABL+ leukemia stem cells. Nanomedicine (Lond) 5: 419-431.
47. Das M, Mohanty C, Sahoo SK, (2009) Ligand-based targeted therapy for cancer tissue. Expert Opinion on Drug Delivery 6: 285-304.
48. Yuan H, Li X, Wu J, Li J, Qu X, et al. (2008) Strategies to overcome or circumvent P-glycoprotein mediated multidrug resistance. Curr Med Chem 15: 470-476.
49. Misra R, Acharya S, Sahoo SK, (2010) Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Discov Today 15: 842-850.
50. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, et al. (1996) Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56: 816-825.
51. Yamada H, Tada-Oikawa S, Uchida A, Kawanishi S, (1999) TRAIL causes cleavage of bid by caspase-8 and loss of mitochondrial membrane potential resulting in apoptosis in BJAB cells. Biochem Biophys Res Commun 265: 130-133.
52. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X, (1998) Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-490.
53. Janssen K, Pohlmann S, Janicke R, Schulze-Osthoff K, Fischer U, (2007) Apaf-1 and caspase-9 deficiency prevents apoptosis in a Bax-controlled pathway and promotes clonogenic survival during paclitaxel treatment. Blood 110: 3662-3672.
54. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, et al. (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372: 739-746.
55. Kohmura K, Miyakawa Y, Kawai Y, Ikeda Y, Kizaki M, (2004) Different roles of p38 MAPK and ERK in STI571-induced multi-lineage differentiation of K562 cells. J Cell Physiol 198: 370-376.
56. Wong S, McLaughlin J, Cheng D, Witte ON, (2003) Cell context-specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors. Blood 101: 4088-4097.
57. Wang TH, Wang HS, Ichijo H, Giannakakou P, Foster JS, et al. (1998) Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. J Biol Chem 273: 4928-4936.
58. Wisdom R, Johnson RS, Moore C, (1999) c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. Embo J 18: 188-197.
59. Acharya S, Dilnawaz F, Sahoo SK, (2009) Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials 30 5737-5750.
60. Alexiou C, Schmidt A, Klein R, Hulin P, Bergemann C, et al. (2002) Magnetic drug targeting: biodistribution and dependency on magnetic field strength. J Magnetism Magn Mater 252: 363-366.
61. Daffner RH, Lupetin AR, Dash N, Deeb ZL, Sefczek RJ, et al. (1986) MRI in the detection of malignant infiltration of bone marrow. AJR Am J Roentgenol 146: 353-358.
62. McKinstry CS, Steiner RE, Young AT, Jones L, Swirsky D, et al. (1987) Bone marrow in leukemia and aplastic anemia: MR imaging before, during, and after treatment. Radiology 162: 701-707.
63. Misra R, Sahoo SK, (2011) Co-formulation of doxorubicin and curcumin in poly (D, L-lactide-co-glycolide) nanoparticles suppress the development of multi drug resistance in K562 cells. Mol Pharm 8: 852-866.
64. Vandana M, Sahoo SK, (2010) Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer. Biomaterials 31: 9340-9356.
65. Mohanty C, Sahoo SK, (2010) The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials 31: 6597-6611.
66. Heliez C, Baricault L, Barboule N, Valette A, (2003) Paclitaxel increases p21 synthesis and accumulation of its AKT-phosphorylated form in the cytoplasm of cancer cells. Oncogene 22: 3260-3268.